Immune repertoire is termed as the combination of B cell receptors (BCR) and T cell receptors (TCR) that makes the organism’s adaptive immune system. It is widely used in biomarker discovery to improve the success rate & cost-effectiveness of rational drug development. It is highly applicable in infectious disease research, cancer immunotherapy, biomarker discovery and asthma & allergy research. It assists researchers and scientist in understanding or examining adaptive immune-mediated diseases.
According to study, “Global Immune Repertoire Sequencing Market Size study, by Type (Assay Kits, Software & Services), by Application (Biomarker Discovery, Infectious Diseases, Vaccine Development & Efficacy, Cancer Immunotherapy, Autoimmune Diseases, Transplant Rejection & Tolerance, Others), by End-User (Academic Institutes, Research Center Diagnostic Laboratories, Others) and Regional Forecasts 2018-2025” the key companies operating in the global immune repertoire sequencing market are Oxford Nanopore Technologies Ltd., Hoffmann-La Roche Ltd., Illumina Inc., Abvitro (Now Juno Therapeutics), Irepertoire, Inc., Archerdx Inc., Adaptive Biotechnologies, Thermo Fischer Scientific, Pacific Biosciences of California Inc., Takara Bio Inc., QIAGEN N.V., Agilent Technologies, BGI. The key players are launching new products in the market, in order to enhance its market share. Such innovative products are addressing numerous clinical needs of patients, which are estimated to create conducive environment for growth of the immune repertoire sequencing market.
Based on product type, immune repertoire sequencing market is segmented into analytical software, assay, kits & reagent, instrument and services. Analytical software includes BCR analysis solutions, TCR analysis solutions and TCR & BCR analysis solutions. Assay, kits & reagent includes BCR kits (mouse BCR kits and human BCR kits) and TCR kits (mouse TCR kits and human TCR kits). Instrument products include polymerase chain reaction (PCR) and Next Generation Sequencing (NGS). Additionally, services include sequencing services, pre-sequencing services and data analysis services. Based on application, market is segmented into biomarker discovery, infectious disease research, autoimmune diseases, immunodeficiency identification, cancer immunotherapy, vaccine development, asthma & allergy research and others. In addition, based on end-users, market is segmented into diagnostic labs, research institutes, pharmaceutical & biotech companies and others.
The immune repertoire sequencing market is driven by growth in technological advancements for instance high-throughput screening, high adoption rate of immune repertoire sequencing with new technology, new software-based platforms, and growth in research & development (R&D) activities, followed by new launches of novel products, rise in prevalence of cancer and rapid increase in multiple therapeutic areas like infectious diseases, pain management, cardiology, and oncology. However, high cost related with sequencing platform & data analytics services and lack of awareness about the cancer diseases treatment may impact the market. Moreover, increase in international collaboration in immune repertoire sequencing projects is a key opportunity for market.
Based on geography, the North-American region dominates the immune repertoire sequencing market owing to high presence of key players and rise in focus on developing novel technologies in the region. The European and Asian-Pacific regions are predictable to exhibit higher growth due to rapid growth in immune repertoire sequencing and rise in usage of immune repertoire sequencing in oncology research over the forecast period. In near future, it is projected that the market will be reached at rapid pace caused by high prevalence of infectious diseases and rise in funding by the government bodies to support international innovative projects & marketable innovative products, services and processes during the forecast period.
For more information on the research report, refer to below link:-
Ankur Gupta, Head Marketing & Communications